Grace Therapeutics Inc. reported QQ1 2024 results with no reported revenue and a quarterly operating loss driven primarily by research and development and general administrative expenses. The company posted an operating loss of $4.963 million and a net loss of $2.617 million for the quarter ended June 30, 2024, translating to earnings per share of −$0.24. R&D expenses totaled $2.708 million and SG&A (general and administrative) expenses were $2.254 million, reflecting continued investment in the company’s early-stage pipeline ( GTX104, GTX102, GTX101). Operating cash flow was negative $(3.596) million, with a net cash outflow for the quarter of $(3.611) million and ending cash (per cash flow) around $19.4–$21.6 million depending on the line item, versus start-of-quarter cash of approximately $23.0 million. The balance sheet shows substantial intangible assets ($41.128 million) and goodwill ($8.138 million), and a robust equity base, with total assets of $73.0 million and total stockholders’ equity of $64.0 million. The company carries no material short-term debt and maintains an unusually high current ratio (~7.9), signaling strong liquidity to fund ongoing R&D initiatives, albeit with a lack of near-term revenue catalysts. As there is no earnings call transcript provided, management commentary and forward-looking guidance could not be incorporated from an official source for QQ1 2024. Investors should monitor pipeline milestones ( GTX104, GTX102, GTX101), potential strategic partnerships, and any interim updates on regulatory or clinical progress. Overall, the stock remains highly speculative, with a clear runway risk if financing is not obtained to sustain the pipeline investment.